These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 2159105)

  • 21. Effects of SIN-1 on electrical responses of the smooth muscle of the canine saphenous vein.
    Komori K; Vanhoutte PM
    J Cardiovasc Pharmacol; 1989; 14 Suppl 11():S62-6. PubMed ID: 2484702
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Molsidomine: importance in treatment of circulation disorders].
    Kmieć M; Ochmański W
    Przegl Lek; 1998; 55(10):532-6. PubMed ID: 10224868
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The importance of Lopion (molsidomine) in the therapy of myocardial ischemia and angina pectoris].
    Trifunović S; Pavlović K
    Med Pregl; 1987; 40(1-2):17-21. PubMed ID: 3657717
    [No Abstract]   [Full Text] [Related]  

  • 24. Contribution of nitric oxide and prostanoids to the cardiac electrophysiological and coronary vasomotor effects of diadenosine polyphosphates.
    Stavrou BM; Sheridan DJ; Flores NA
    J Pharmacol Exp Ther; 2001 Aug; 298(2):531-8. PubMed ID: 11454914
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Acute and long-term effects of placebo and molsidomine on pulmonary artery pressure and on workload in patients with coronary heart disease].
    Jansen W; Osterspey A; Schell U; Tauchert M
    Schweiz Rundsch Med Prax; 1986 Oct; 75(41):1210-4. PubMed ID: 3787007
    [No Abstract]   [Full Text] [Related]  

  • 26. Superoxide does not inhibit glyceryl trinitrate-rabbit aortic strip-mediated relaxation of rabbit Taenia coli. Evidence against a role for nitric oxide itself as the smooth muscle active drug metabolite?
    Hussain AS; Brien JF; Marks GS; Nakatsu K
    Drug Metab Dispos; 1996 Jul; 24(7):780-5. PubMed ID: 8818576
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Gallopamil and molsidomine in patients with coronary heart disease. A comparative study].
    Zebe H
    Fortschr Med; 1989 Feb; 107(5):134-8. PubMed ID: 2651251
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Biorhythm influence on the course of ischemic heart disease during combined treatment with molsidomine and anaprilin].
    Vakaliuk IP
    Ter Arkh; 1986; 58(12):49-50. PubMed ID: 3824212
    [No Abstract]   [Full Text] [Related]  

  • 29. [Parenteral administration of molsidomine].
    Klaus W
    Med Klin (Munich); 1994 Jul; 89 Suppl 2():1. PubMed ID: 7968891
    [No Abstract]   [Full Text] [Related]  

  • 30. [Effect duration and dose-response relation of molsidomine in patients with coronary heart disease].
    Fach WA; Becker HJ
    Z Kardiol; 1984 Oct; 73(10):613-22. PubMed ID: 6393621
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Treatment of stress-induced angina pectoris and chronic heart failure with molsidomine].
    Beyerle A; Rudolph W
    Med Klin (Munich); 1986 Jan; 81(2):41-4. PubMed ID: 3537664
    [No Abstract]   [Full Text] [Related]  

  • 32. [Problems in long-term therapy of coronary heart disease: pharmacotherapy].
    Gilfrich HJ
    Med Klin (Munich); 1987 Jan; 1():29-32. PubMed ID: 3106752
    [No Abstract]   [Full Text] [Related]  

  • 33. [Redistribution of the coronary blood flow, functional improvement of the ischemic myocardium and reduction of the size of an experimental infarction by molsidomine].
    Berdeaux A; Giudicelli JF
    Ann Cardiol Angeiol (Paris); 1983 Dec; 32(8):511-5. PubMed ID: 6364947
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacological evidence that endothelium-derived relaxing factor is nitric oxide: use of pyrogallol and superoxide dismutase to study endothelium-dependent and nitric oxide-elicited vascular smooth muscle relaxation.
    Ignarro LJ; Byrns RE; Buga GM; Wood KS; Chaudhuri G
    J Pharmacol Exp Ther; 1988 Jan; 244(1):181-9. PubMed ID: 2826766
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Endothelial regulation of coronary microvascular tone under physiological and pathophysiological conditions.
    Chilian WM; Kuo L; DeFily DV; Jones CJ; Davis MJ
    Eur Heart J; 1993 Nov; 14 Suppl I():55-9. PubMed ID: 7904942
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Some pharmacological properties of organic nitrates.
    Osnes JB
    Scand J Clin Lab Invest Suppl; 1984; 173():19-25. PubMed ID: 6098958
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exogenous hydrogen sulfide inhibits superoxide formation, NOX-1 expression and Rac1 activity in human vascular smooth muscle cells.
    Muzaffar S; Shukla N; Bond M; Newby AC; Angelini GD; Sparatore A; Del Soldato P; Jeremy JY
    J Vasc Res; 2008; 45(6):521-8. PubMed ID: 18463417
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nitroaspirins and morpholinosydnonimine but not aspirin inhibit the formation of superoxide and the expression of gp91phox induced by endotoxin and cytokines in pig pulmonary artery vascular smooth muscle cells and endothelial cells.
    Muzaffar S; Shukla N; Angelini G; Jeremy JY
    Circulation; 2004 Aug; 110(9):1140-7. PubMed ID: 15326075
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Endothelial function in coronary artery disease.
    Cosentino F; Lüscher TF
    Cardiologia; 1997 Dec; 42(12):1221-7. PubMed ID: 9534315
    [No Abstract]   [Full Text] [Related]  

  • 40. A low dose of forskolin increases cyclic AMP levels and cyclic AMP dependent protein kinase activity in bovine coronary arteries without causing relaxation.
    Vegesna RV; Diamond J
    Proc West Pharmacol Soc; 1984; 27():189-92. PubMed ID: 6093128
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.